2Jones SP. Cyclodextrlna in the pharmaceutical sciences[J]. Acta Pharm Technal, 1984,30(3) :213.
3Duchene D, Wouessidjewe D. The current state of β-cyclodextrin in the pharmaceutics [ J ]. Acta Pharm Technol, 1990,36 ( 1 ): 11.
4Banghan AD,Standish MM,Watkins JC. Diffusion of univalentions across the amellae of swollen phospholipid[J]. Mol Bio1,1965,13(2):228.
5Canto GS, Dallmora SL, Oliveira AG. Piroxicam encapsulated in lipo- some: characterization and in vivo evaluation of topical antiinflammatory effect[J]. Drug Dev Ind Pharm, 1999,25 (12) : 1 235.
6Patel VB, Misra AN, Marfatia YS. A topical dosage form of liposomal clofazimine: research and clinical implications[J]. Pharmazie, 1999, 54 (6) :448.
7Lee EH,Kim A,Oh YK,et al. Effect of edge activators on the forma- tion and transfection efficiency of ultradeformable liposomes[J]. Bioma- terials, 2005,26 (2) : 205.
8Cevc G,Schatzkein A,Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size mea- surements [ J ]. Biuchem Biophys Acta, 2002,1 564 ( 1 ) : 21.
9Ceve G, Gebauer D, Stieber J, et al. UItraflexible vesicles, Transfer- somes,have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin[J]. Biochim Biophys Acta, 1995,1 365(2) :201.
10Ceve G, Gebauer D, Stieber J, et al. New,highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers,Transfersomes[J]. Biochim Biophys Acta,2001,1514(2) : 191.
